Navigation Links
Mylan's Matrix Receives First and Only Tentative FDA Approval Under PEPFAR for Generic Version of Atripla(R) HIV Treatment
Date:8/18/2009

PITTSBURGH, Aug. 18 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that Matrix Laboratories, an Indian company in which Mylan owns a controlling stake, has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for a fixed-dose combination (FDC) of Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Tablets, 600 mg/200 mg/300 mg. This is the first and only generic version of this product and will be eligible for purchase outside the U.S. in many developing countries.

Mylan President Heather Bresch said: "This critical approval only further strengthens Mylan and Matrix's efforts to expand access to life-saving, affordable AIDS treatments for people living with HIV/AIDS in developing countries. Matrix's generic fixed-dose combination will dramatically improve access to this more patient-friendly medication while reducing the cost of treatment. Our commitment to growing Matrix's ARV (antiretroviral) franchise goes hand-in-hand with our desire to raise the standard of care in developing countries to the levels available in countries like the U.S."

The Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate FDC is the generic version of Gilead Sciences' Atripla(R) Tablets, which are indicated for the treatment of HIV-1 infection in adults. It combines three anti-AIDS medicines into a single daily dose for either first- or second-line treatment and is one of the best-selling AIDS products in developed countries, with approximately $1.6 billion in U.S. sales alone for the twelve months ending June 30, according to IMS Health. Until now, a generic version of this product has not been available in any market. Cocktails co
'/>"/>

SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Sigma-Aldrich Offers Customizable Synthetic Extracellular Matrix for Stem Cell Research
2. Matrixx Initiatives, Inc. Sets Time for Discussion of First Quarter Fiscal 2010 Financial Results
3. MedInsights Partners With myMatrixx(TM) for Workers Compensation Pharmacy Benefit Management
4. Matrixx Initiatives Confirms Voluntary Recall of Zicam Cold Remedy Nasal Gel, Zicam Cold Remedy Gel Swabs
5. Matrixx Initiatives, Inc. Sets Time for Discussion of Recent FDA Action
6. Matrixx Initiatives Voluntarily Withdraws Zicam Cold Remedy Swabs, Zicam Cold Remedy Nasal Gel
7. Matrixx Initiatives, Inc. Received a Warning Letter From the Food and Drug Administration
8. Mylan Announces Successful Matrix Delisting Offer
9. Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting
10. Matrixx Initiatives, Inc. Reports Fiscal 2009 Revenue Increased 11% to a Record $111.6 Million and Earnings Per Share Increased 40% to $1.46
11. CorMatrix Cardiovascular to Present on its ECM Technology(TM) at the Annual Advanced Cardiac Techniques in Surgery (ACTS) Symposium in New York, N.Y.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 31, 2014 Fundraising support for fighting cancer ... than losses. At noon on Monday, November 10 in the ... (SSMH), greater than 20 Susquehanna Health (SH) employees and community ... awareness and funds for the new Cancer Center at SSMH. ... for this act of love and support to which many ...
(Date:10/31/2014)... first study of its kind, Rice University researchers have ... cause cancer cells to become metastatic. The research reveals ... cells to both migrate and form new tumors. Researchers ... drugs that interfere with the genetic switches that cancer ... circulating tumor cells -- two of the main players ...
(Date:10/31/2014)... October 31, 2014 The Memory Healer review ... by Alexander Lynch, whose father suffered from Alzheimer's disease. ... moment, caused by his father's disease. His father pointed a ... the crucial moment when the author of this method understood ... , The Memory Healer program is based on years ...
(Date:10/31/2014)... CA (PRWEB) October 31, 2014 ... also has amazing health effects for practitioners. ... by a Doctor of Science and Movement specializing ... his dedication to pelvic floor reeducation that traditional ... urinary incontinence, Diastasis Recti, Prolepses, etc. , The ...
(Date:10/31/2014)... Lake City, UT (PRWEB) October 31, 2014 ... announce the new Activz Silver line offering ... and cleansing wipes. For over a century, silver has ... formula found in Activz Silver products is the most ... U.S. patents, has a unique chemical structure that supports ...
Breaking Medicine News(10 mins):Health News:Susquehanna Health Soldiers + Sailors Memorial Hospital Razing Heads to Fight Cancer 2Health News:Decoding the emergence of metastatic cancer stem cells 2Health News:Decoding the emergence of metastatic cancer stem cells 3Health News:"Memory Healer" Review Reveals a New Natural Remedy Guide for Managing Memory Loss 2Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 2Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 3Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 2Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 3Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 4
... News) -- Heart disease patients with high blood pressure ... drugs (NSAIDs) are at greater risk for heart attack, ... NSAIDS include popular medications such as such as aspirin, ... are published in the July issue of The ...
... Gordon HealthDay Reporter , THURSDAY, July 14 (HealthDay News) ... you probably memorized a lot more information -- such as phone ... a new study has found that the brain just doesn,t remember ... been saved on a computer. What people may remember, however, is ...
... transplant survival more than doubled in recent years for ... Research Hospital, with patients who lacked genetically matched donors ... to be the best ever reported for leukemia patients ... expected to make transplantation a treatment option for more ...
... can be admirable or romantic. In a cancerous tumor, it ... cells that have strayed from their original location to insinuate their ... way of determining whether a newly formed tumor is more likely ... the body. In a study published in the July 12 ...
... percent of patients with primary or metastatic cancer ... seizures, confusion, difficulty swallowing and visual disturbances. These ... brain invasion from cancer called neoplastic meningitis. Santosh ... San Diego School of Medicine and colleagues have ...
... 14 (HealthDay News) -- New research suggests that training ... other people could help them overcome anxiety and prevent ... Oxford University in the United Kingdom found that training ... negative interpretations of unclear social situations could influence how ...
Cached Medicine News:Health News:Certain Painkillers May Raise Odds of Stroke, Heart Attack: Study 2Health News: Can You Google Your Memory? 2Health News: Can You Google Your Memory? 3Health News: Can You Google Your Memory? 4Health News:Bone marrow transplant survival more than doubles for young high-risk leukemia patients 2Health News:Bone marrow transplant survival more than doubles for young high-risk leukemia patients 3Health News:Early-stage melanoma tumors contain clues to metastatic potential 2Health News:Early-stage melanoma tumors contain clues to metastatic potential 3Health News:Novel combined therapy extends life, diminishes pain in brain cancer patients 2Health News:Training in Positive Thinking May Help Anxious Teens 2
(Date:10/31/2014)... , Oct. 31, 2014  Zacks.com announces the list of stocks ... analysts discuss the latest news and events impacting stocks and the ... AMGN - Free Report ), Celgene (Nasdaq: ... BIIB - Free Report ), Market Vectors Biotech ETF ... S&P Biotech ETF (AMEX: XBI - Free Report ...
(Date:10/31/2014)... , Oct. 31, 2014 /CNW Telbec/ - ... with its strategic plan, for accelerated growth in terms ... 32.6% and revenues reached $17,862,341. Net income amounted to ... threshold for the first time in the Company,s history. ... the Company joined the forces of its subsidiaries, merging ...
(Date:10/31/2014)... 2014 Though therapies are in their nascent ... show an annual increase of 16.2% over the 2010-2020 ... billion, according to Kalorama Information,s report, Stem Cell ... therapeutics that have gained or are expected to gain ... developers tackle ever more complicated conditions, stem cell therapies ...
Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 2The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 3The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 4The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 5The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 6The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 7Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 2Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 3Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 4Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 5Report: Stem Cell Technologies Market Growing 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: